Which has stronger valuation and earnings, AXGN or GKOS?

AxoGen has higher earnings, but lower revenue than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 9.56 -$15.70M -$0.64 N/A Glaukos $507.44M 14.44 -$187.69M -$3.28 N/A

Is AXGN or GKOS more profitable?

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% Glaukos -34.34% -6.92% -5.25%

Does the media refer more to AXGN or GKOS?

In the previous week, AxoGen had 1 more articles in the media than Glaukos. MarketBeat recorded 3 mentions for AxoGen and 2 mentions for Glaukos. Glaukos' average media sentiment score of 1.23 beat AxoGen's score of 0.26 indicating that Glaukos is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Glaukos 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BLCO or AXGN more profitable?

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Bausch + Lomb -4.21% 3.60% 1.69% AxoGen -13.21% -9.63% -6.26%

Does the media favor BLCO or AXGN?

In the previous week, Bausch + Lomb had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Bausch + Lomb and 3 mentions for AxoGen. Bausch + Lomb's average media sentiment score of 0.72 beat AxoGen's score of 0.26 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate STVN or AXGN?

AxoGen has a consensus target price of $46.50, suggesting a potential upside of 8.64%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 AxoGen 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.73

Which has stronger valuation & earnings, STVN or AXGN?

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 4.19 €158.21M €0.59 31.49 AxoGen $238.11M 9.56 -$15.70M -$0.64 N/A

Does the media favor STVN or AXGN?

In the previous week, Stevanato Group had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Stevanato Group and 3 mentions for AxoGen. Stevanato Group's average media sentiment score of 0.67 beat AxoGen's score of 0.26 indicating that Stevanato Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, LQDA or AXGN?

AxoGen has lower revenue, but higher earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $288.07M 19.09 -$68.92M $0.14 441.79 AxoGen $238.11M 9.56 -$15.70M -$0.64 N/A

Is LQDA or AXGN more profitable?

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% AxoGen -13.21% -9.63% -6.26%

Does the media prefer LQDA or AXGN?

In the previous week, Liquidia had 5 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for Liquidia and 3 mentions for AxoGen. AxoGen's average media sentiment score of 0.26 beat Liquidia's score of -0.15 indicating that AxoGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, AXGN or LIVN?

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 9.56 -$15.70M -$0.64 N/A LivaNova $1.39B 2.86 -$242.47M $1.95 37.11

Is AXGN or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% LivaNova 7.48% 16.48% 7.59%

Does the media refer more to AXGN or LIVN?

In the previous week, AxoGen and AxoGen both had 3 articles in the media. AxoGen's average media sentiment score of 0.26 beat LivaNova's score of 0.09 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

AxoGen (AXGN) Competitors

$42.80 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$42.72 -0.08 (-0.18%)

As of 04:17 AM Eastern

Compare

AXGN vs. GKOS, BLCO, STVN, LQDA, and LIVN

Should you buy AxoGen stock or one of its competitors? MarketBeat compares AxoGen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AxoGen include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Liquidia (LQDA), and LivaNova (LIVN). These companies are all part of the "medical equipment" industry.

How does AxoGen compare to Glaukos?

AxoGen (NASDAQ:AXGN) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

In the previous week, AxoGen had 1 more articles in the media than Glaukos. MarketBeat recorded 3 mentions for AxoGen and 2 mentions for Glaukos. Glaukos' average media sentiment score of 1.23 beat AxoGen's score of 0.26 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has a net margin of -13.21% compared to Glaukos' net margin of -34.34%. Glaukos' return on equity of -6.92% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Glaukos	-34.34%	-6.92%	-5.25%

AxoGen has higher earnings, but lower revenue than Glaukos. AxoGen is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	9.56	-$15.70M	-$0.64	N/A
Glaukos	$507.44M	14.44	-$187.69M	-$3.28	N/A

AxoGen presently has a consensus target price of $46.50, suggesting a potential upside of 8.64%. Glaukos has a consensus target price of $146.17, suggesting a potential upside of 17.13%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

80.3% of AxoGen shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Glaukos beats AxoGen on 11 of the 16 factors compared between the two stocks.

How does AxoGen compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

AxoGen has lower revenue, but higher earnings than Bausch + Lomb. AxoGen is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.08	-$360M	-$0.62	N/A
AxoGen	$238.11M	9.56	-$15.70M	-$0.64	N/A

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Bausch + Lomb had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Bausch + Lomb and 3 mentions for AxoGen. Bausch + Lomb's average media sentiment score of 0.72 beat AxoGen's score of 0.26 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch + Lomb has a net margin of -4.21% compared to AxoGen's net margin of -13.21%. Bausch + Lomb's return on equity of 3.60% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
AxoGen	-13.21%	-9.63%	-6.26%

Bausch + Lomb currently has a consensus price target of $17.92, suggesting a potential upside of 15.73%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 8.64%. Given Bausch + Lomb's higher possible upside, equities research analysts clearly believe Bausch + Lomb is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Bausch + Lomb beats AxoGen on 9 of the 16 factors compared between the two stocks.

How does AxoGen compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Stevanato Group has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.19	€158.21M	€0.59	31.49
AxoGen	$238.11M	9.56	-$15.70M	-$0.64	N/A

AxoGen has a consensus target price of $46.50, suggesting a potential upside of 8.64%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stevanato Group had 2 more articles in the media than AxoGen. MarketBeat recorded 5 mentions for Stevanato Group and 3 mentions for AxoGen. Stevanato Group's average media sentiment score of 0.67 beat AxoGen's score of 0.26 indicating that Stevanato Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Stevanato Group has a net margin of 11.76% compared to AxoGen's net margin of -13.21%. Stevanato Group's return on equity of 10.27% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
AxoGen	-13.21%	-9.63%	-6.26%

Summary

Stevanato Group beats AxoGen on 10 of the 17 factors compared between the two stocks.

How does AxoGen compare to Liquidia?

Liquidia (NASDAQ:LQDA) and AxoGen (NASDAQ:AXGN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 80.3% of AxoGen shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 2.4% of AxoGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, AxoGen has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Liquidia currently has a consensus target price of $55.63, indicating a potential downside of 10.06%. AxoGen has a consensus target price of $46.50, indicating a potential upside of 8.64%. Given AxoGen's higher possible upside, analysts clearly believe AxoGen is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Liquidia had 5 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for Liquidia and 3 mentions for AxoGen. AxoGen's average media sentiment score of 0.26 beat Liquidia's score of -0.15 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has lower revenue, but higher earnings than Liquidia. AxoGen is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$288.07M	19.09	-$68.92M	$0.14	441.79
AxoGen	$238.11M	9.56	-$15.70M	-$0.64	N/A

Liquidia has a net margin of 7.74% compared to AxoGen's net margin of -13.21%. Liquidia's return on equity of 46.82% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
AxoGen	-13.21%	-9.63%	-6.26%

Summary

Liquidia beats AxoGen on 11 of the 17 factors compared between the two stocks.

How does AxoGen compare to LivaNova?

AxoGen (NASDAQ:AXGN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

AxoGen has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

In the previous week, AxoGen and AxoGen both had 3 articles in the media. AxoGen's average media sentiment score of 0.26 beat LivaNova's score of 0.09 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LivaNova has a net margin of 7.48% compared to AxoGen's net margin of -13.21%. LivaNova's return on equity of 16.48% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
LivaNova	7.48%	16.48%	7.59%

80.3% of AxoGen shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 8.64%. LivaNova has a consensus price target of $79.38, suggesting a potential upside of 9.69%. Given LivaNova's higher possible upside, analysts plainly believe LivaNova is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

AxoGen has higher earnings, but lower revenue than LivaNova. AxoGen is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	9.56	-$15.70M	-$0.64	N/A
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11

Summary

LivaNova beats AxoGen on 8 of the 15 factors compared between the two stocks.

Get AxoGen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AXGN vs. The Competition

Export

Metric	AxoGen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.28B	$7.11B	$6.47B	$11.98B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	-66.88	45.87	24.08	23.62
Price / Sales	9.56	44.52	516.49	109.93
Price / Cash	N/A	25.19	26.99	37.25
Price / Book	15.34	6.95	10.39	6.66
Net Income	-$15.70M	$159.22M	$3.57B	$337.72M
7 Day Performance	10.54%	-2.02%	-0.92%	-3.71%
1 Month Performance	1.76%	3.39%	3.55%	0.97%
1 Year Performance	291.94%	-1.02%	23.80%	25.35%

AxoGen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AXGN AxoGen	2.163 of 5 stars	$42.80 flat	$46.50 +8.6%	+291.9%	$2.28B	$238.11M	N/A	450	Positive News Analyst Downgrade
GKOS Glaukos	2.786 of 5 stars	$120.95 +0.6%	$146.17 +20.8%	+34.1%	$7.06B	$507.44M	N/A	1,094	Positive News High Trading Volume
BLCO Bausch + Lomb	4.1431 of 5 stars	$15.95 +0.2%	$18.08 +13.4%	+32.4%	$5.68B	$5.10B	N/A	13,000
STVN Stevanato Group	2.9225 of 5 stars	€18.12 +0.6%	N/A	-21.9%	€5.49B	€1.34B	30.72	6,010	Gap Up
LQDA Liquidia	2.2818 of 5 stars	$60.98 flat	$49.33 -19.1%	+241.0%	$5.42B	$158.32M	435.60	50	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AXGN) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Competitors